SG63621A1 - Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines - Google Patents

Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines

Info

Publication number
SG63621A1
SG63621A1 SG1996007722A SG1996007722A SG63621A1 SG 63621 A1 SG63621 A1 SG 63621A1 SG 1996007722 A SG1996007722 A SG 1996007722A SG 1996007722 A SG1996007722 A SG 1996007722A SG 63621 A1 SG63621 A1 SG 63621A1
Authority
SG
Singapore
Prior art keywords
hiv
cytotoxic
vaccines
lymphocyte
lipopeptide
Prior art date
Application number
SG1996007722A
Inventor
Christophe Boutillon
Frederic Martinon
Christian Sergheraert
Remy Magne
Helena Gras-Masse
Elisabeth Gomard
Andre Tartar
Jean-Paul Levy
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9403372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG63621(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Publication of SG63621A1 publication Critical patent/SG63621A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The use of a lipopeptide (I) is claimed for the immunization of humans or animals against pathogens or tumor cells, where (I) contains: (i) a peptide component having 10-40 (preferably 10-20) amino acids; (ii) at least one antigenic determinant which specifically induces cytotoxic T-lymphocytes; and (iii) one or more chains derived from N- epsilon -palmitoyl-L-lysine, coupled to the carboxy functions of the aminoacids. An Independent claim is included for a lipopeptide (I') for immunization against HIV-1 or HIV-2, comprising (I) as above in which component (i) is a fragment of an HIV-1 or HIV-2 protein.
SG1996007722A 1990-12-18 1991-12-18 Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines SG63621A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9015870A FR2670787B1 (en) 1990-12-18 1990-12-18 LIPOPEPTIDES INDUCING CYTOTOXIC T CELLS AND USE AS VACCINES.

Publications (1)

Publication Number Publication Date
SG63621A1 true SG63621A1 (en) 1999-11-16

Family

ID=9403372

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996007722A SG63621A1 (en) 1990-12-18 1991-12-18 Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines

Country Status (10)

Country Link
EP (3) EP1065212A3 (en)
JP (2) JP3821305B2 (en)
AT (1) ATE185148T1 (en)
CA (1) CA2057828C (en)
DE (1) DE69131662T2 (en)
DK (1) DK0491628T3 (en)
ES (1) ES2137160T3 (en)
FR (1) FR2670787B1 (en)
GR (1) GR3031889T3 (en)
SG (1) SG63621A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547681A2 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. Synthetic peptides comprising a cyclic HIV principal neutralizing determinant and a lipopeptide
FR2771640B1 (en) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med MIXED MICELLES OF LIPOPEPTIDES FOR INDUCING AN IMMUNE RESPONSE AND THEIR USES FOR THERAPEUTIC PURPOSES
FR2776926B1 (en) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med LYMPHOCYTARY T CYTOTOXICITY T INDUCING LIPOPEPTIDES CARRYING AT LEAST ONE AUXILIARY T EPITOPE, AND THEIR USES FOR VACCINATION
FR2821556B1 (en) * 2001-03-02 2003-04-25 Aventis Pasteur USE OF LIPOPEPTIDES FOR IMMUNOTHERAPY OF HIV + SUBJECTS
WO2002076485A2 (en) 2001-03-27 2002-10-03 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
TWI511738B (en) 2005-06-28 2015-12-11 Oncothyreon Inc Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
US9562104B2 (en) 2009-03-10 2017-02-07 Baylor Research Institute Anti-CD40 antibodies
CA2754764A1 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
EP3219732A1 (en) 2009-03-10 2017-09-20 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
KR20140023903A (en) 2011-02-24 2014-02-27 온코타이레온, 인코포레이티드 Muc1 based glycolipopeptide vaccine with adjuvant
AR085573A1 (en) 2011-03-25 2013-10-09 Baylor Res Inst COMPOSITIONS AND IMMUNIZATION METHODS AGAINST THE VIRUS OF HEPATITIS C
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
CN106103483A (en) 2014-01-13 2016-11-09 贝勒研究院 The novel vaccine of the related disease of anti-HPV with HPV
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831547B (en) * 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
ATE72123T1 (en) * 1985-04-19 1992-02-15 Wistar Inst VACCINE FOR GENERATING A VIRUS-PROTECTIVE IMMUNOGENIC T-CELL RESPONSE.
EP0306912A3 (en) * 1987-09-08 1989-07-05 Albany Medical College Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi

Also Published As

Publication number Publication date
EP0945461A1 (en) 1999-09-29
EP1065212A3 (en) 2001-01-10
ATE185148T1 (en) 1999-10-15
ES2137160T3 (en) 1999-12-16
DE69131662D1 (en) 1999-11-04
GR3031889T3 (en) 2000-02-29
JPH04295498A (en) 1992-10-20
FR2670787B1 (en) 1995-06-23
EP0491628A2 (en) 1992-06-24
EP1065212A2 (en) 2001-01-03
FR2670787A1 (en) 1992-06-26
EP0491628B1 (en) 1999-09-29
JP3821305B2 (en) 2006-09-13
JP2004043501A (en) 2004-02-12
DE69131662T2 (en) 2000-04-06
CA2057828C (en) 2007-06-12
CA2057828A1 (en) 1992-06-19
DK0491628T3 (en) 2000-04-10
EP0491628A3 (en) 1992-07-22

Similar Documents

Publication Publication Date Title
SG63621A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
DK532184A (en) ANTIGEN AMINO ACID SEQUENCES
HK1053662A1 (en) Gag antigen and its use for the detection of lav infection and in immunogenic compositions
IL102687A0 (en) Method for enhancing immunogenicity
GB2255093A (en) Hiv-1 core protein fragments
BR0010720A (en) Antigenic neisseria peptides
GB8912651D0 (en) Peptide fragments of hiv
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
GB9201468D0 (en) Peptide fragments of hiv
NZ316970A (en) Viral recombinant pseudo-particles and vaccinal and anti-tumoral applications
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
NZ224251A (en) Synthetic rhinovirus (hrv) peptides and vaccines
ZA907944B (en) Hiv related peptides
NZ230996A (en) Immunogenic recombinant polypeptides and their use in the production of neutralising antibodies against viral haemorrhagic septicaemia virus
GB9027901D0 (en) Acellular vaccine